NCT00004816View on ClinicalTrials.gov

A Maintenance Extension of Phase I Pilot Study of Chimeric Anti-CD4 Antibody M-T412 in Patients With Multiple Sclerosis

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 31, 1995

Conditions
Multiple Sclerosis
Interventions
DRUG

monoclonal antibody M-T412

All Listed Sponsors
collaborator

Stanford University

OTHER

lead

National Center for Research Resources (NCRR)

NIH

NCT00004816 - A Maintenance Extension of Phase I Pilot Study of Chimeric Anti-CD4 Antibody M-T412 in Patients With Multiple Sclerosis | Biotech Hunter | Biotech Hunter